CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.93 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 718.03K shares, a 42.21% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 2.21M shares, a 26.62% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 1.42M shares, a 565.37% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 90.50K shares, a 89.70% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.77M shares, a 184.33% increase from fiscal 2024.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.03M shares, a 3956.28% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 50.00K shares, a 98.41% decline from fiscal 2022.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.15M shares, a 21.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 718.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 2.93M shares 10-Q · filed 2026-08-06 | 4.35M shares derived: sum of 3 quarters · filed 2026-08-06 | 4.44M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 2.21M shares 10-Q · filed 2026-05-07 | 3.63M shares derived: sum of 2 quarters · filed 2026-05-07 | 3.72M shares derived: sum of 3 quarters · filed 2026-05-07 | 4.97M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 1.42M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 1.51M shares derived: sum of 2 quarters · filed 2026-03-05 | 2.76M shares derived: sum of 3 quarters · filed 2026-03-05 | 5.77M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 90.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.33M shares derived: sum of 2 quarters · filed 2025-11-06 | 4.34M shares 10-Q · filed 2025-11-06 | 4.56M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 1.24M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 4.25M shares 10-Q · filed 2025-08-12 | 4.47M shares derived: sum of 3 quarters · filed 2025-08-12 | 5.34M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 3.01M shares 10-Q · filed 2025-05-14 | 3.22M shares derived: sum of 2 quarters · filed 2025-05-14 | 4.10M shares derived: sum of 3 quarters · filed 2025-05-14 | 5.04M shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 214.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 1.09M shares derived: sum of 2 quarters · filed 2025-03-25 | 2.03M shares derived: sum of 3 quarters · filed 2025-03-25 | 2.03M shares 10-K · filed 2025-03-25 |
| 2024-09-30 | 878.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.81M shares derived: sum of 2 quarters · filed 2024-11-12 | 1.81M shares 10-Q · filed 2024-11-12 | 1.81M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 935.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 935.10K shares 10-Q · filed 2024-08-14 | 935.10K shares derived: sum of 3 quarters · filed 2024-08-14 | 935.10K shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | 0.00 shares derived: sum of 2 quarters · filed 2024-05-15 | 0.00 shares derived: sum of 3 quarters · filed 2024-05-15 | 50.00K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-28 | 50.00K shares derived: sum of 3 quarters · filed 2024-03-28 | 50.00K shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 50.00K shares derived: sum of 2 quarters · filed 2023-11-14 | 50.00K shares 10-Q · filed 2023-11-14 | 1.53M shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 50.00K shares 10-Q · filed 2023-08-10 | 1.53M shares derived: sum of 3 quarters · filed 2024-05-15 | 1.53M shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | 1.48M shares derived: sum of 2 quarters · filed 2024-05-15 | 1.48M shares derived: sum of 3 quarters · filed 2024-05-15 | 1.80M shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | 1.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 1.48M shares derived: sum of 2 quarters · filed 2023-03-06 | 1.80M shares derived: sum of 3 quarters · filed 2023-03-06 | 3.15M shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 8.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 318.52K shares derived: sum of 2 quarters · filed 2022-11-14 | 1.67M shares 10-Q · filed 2022-11-14 | 1.88M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 310.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 1.67M shares 10-Q · filed 2022-08-15 | 1.87M shares derived: sum of 3 quarters · filed 2022-08-15 | 1.98M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 1.36M shares 10-Q · filed 2022-05-16 | 1.56M shares derived: sum of 2 quarters · filed 2022-05-16 | 1.67M shares derived: sum of 3 quarters · filed 2022-05-16 | |
| 2021-12-31 | 204.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 316.20K shares derived: sum of 2 quarters · filed 2022-03-07 | 2.59M shares 10-K · filed 2022-03-07 | |
| 2021-09-30 | 111.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 2.39M shares 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | 2.28M shares 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |